Gastrointestinal Cancer

R.M., 61, a retired librarian now restoring her late husband's rose garden, whose cirrhosis and baseline cytopenias raise the mitomycin-vs-cisplatin question in anal cancer chemoradiation. The disagreement is which trial's own long-term follow-up actually earns the citation everyone reaches for first.

D.O., 67, a retired postal worker whose gallbladder cancer turned up only after what everyone assumed was routine gallstone surgery. The disagreement is whether adjuvant capecitabine is still justified once a reader learns BILCAP's own primary survival endpoint fell short of significance.

L.F., 59, who ran a tailoring shop out of her home for over twenty years, now progressing on a HER2 result drawn from resection tissue over a year old. The disagreement is whether to start zanidatamab on that result or re-biopsy first, given how much HER2 status in biliary cancer is known to drift.

A.N., 64, a piano teacher who has had to shorten her lessons since starting chemotherapy, now developing early oxaliplatin neuropathy that forces an early answer to a question IDEA was actually designed to let patients ask. The disagreement is whether her own risk category says six months is still worth the nerve damage.

J.K., 52, a grocery produce manager whose bulky liver metastases are already compressing her bile ducts. The disagreement is whether first-line pembrolizumab's own early-progression risk is one her bilirubin can actually afford to wait out.

T.W., 45, a youth swim coach whose cecal mass was found only because his wife insisted he get checked. The disagreement is whether tumor-sidedness data built on survival in unresectable disease should still govern a decision that's actually about converting his liver metastases to resectable.

V.P., 75, a retired hardware store owner who still comes in most mornings to keep an eye on things, now facing a BRAF V600E-mutant diagnosis. The disagreement is whether encorafenib plus cetuximab, approved only after prior therapy, can reasonably be moved ahead of standard first-line chemotherapy for a frail patient.

C.B., 56, a commercial fishing crew manager who kept working through most of his first six months of chemotherapy. The disagreement is whether his HER2 amplification, itself a known anti-EGFR resistance mechanism, should mean skipping the field's usual second-line drug entirely.

M.D., 49, a long-haul trucker who put off his first colonoscopy for years, found to carry a genotype that slows how his body clears irinotecan. The disagreement is whether FOLFIRINOX's induction advantage still holds once that toxicity risk is genuinely, not just theoretically, elevated.

G.S., 68, a retired postal worker restoring a wooden sailboat, now struggling to swallow solid food. The disagreement is whether adding pembrolizumab to his HER2-targeted regimen still makes sense once the actual approval turns out to be narrower than the trial that inspired it.

H.A., 61, a neighborhood baker who finally handed the ovens to her nephew after early satiety made eating unmanageable, whose biomarker result sits just under the threshold zolbetuximab's own pivotal trials used. The disagreement is whether a borderline result still supports a drug she's already struggling to tolerate feeding-wise.

O.R., a 74-year-old former long-haul trucker who wants the chemotherapy-free dual-checkpoint regimen he's read about. The disagreement is that the trial data behind it actually favor a PD-L1 profile he doesn't have.

B.L., 57, a hospice chaplain who says his own work has taught him more about honest conversations than any training did, progressing on platinum-based chemotherapy. The disagreement is whether retifanlimab's modest, single-arm response rate is genuinely the better second-line choice, on his own terms.

F.N., 63, a retired art teacher who has kept a pottery wheel running through most of her cancer treatment, now progressing with incidental baseline lung changes already on her scans. The disagreement is whether trastuzumab deruxtecan's superior efficacy still makes sense against its own specific lung-toxicity signal.

K.T., 66, who has run a small vineyard for twenty-five years and jokes about where his cirrhosis actually came from, now carrying high-risk esophageal varices alongside unresectable liver cancer. The disagreement is whether the standard regimen's antiangiogenic component is a risk worth taking or a reason to choose the alternative that leaves it out.

R.J., 70, a machinist who still tinkers with small-engine repairs for neighbors, now on his third round of incomplete responses to transarterial chemoembolization. The disagreement is whether the defined criteria for TACE refractoriness have already been met, whatever a third session's continued appeal might suggest.

S.E., 60, who has kept the books for her family's dry-cleaning chain for thirty years and found her tumor "the boring way," on an incidental scan years before any symptom. The disagreement is whether targeted radionuclide therapy can still be the right next step when one of her progressing liver lesions won't take up the tracer the treatment depends on.

P.G., 68, a retired hospital pharmacist now spending her days gardening and babysitting grandchildren, whose ECOG score of 1 doesn't capture the real sarcopenia and weight loss the team can see in front of them. The disagreement is whether performance status alone should decide between FOLFIRINOX and a gentler regimen.

N.V., 55, a high school chemistry teacher determined not to let treatment take the whole year from her students, responding well to platinum chemotherapy. The disagreement is whether maintenance olaparib is worth choosing over a chemotherapy-free interval when POLO's own data show a real progression-free benefit but not an overall-survival one.

Y.M., 51, a produce warehouse manager whose appendectomy for presumed appendicitis came back showing cancer instead. The disagreement is whether extrapolating colon cancer's own adjuvant regimen to a disease with no dedicated trials of its own is genuinely sound, or simply the only option anyone has tried.

D.K., 63, a lifelong hunter and fisherman whose years of tick bites left him with an allergy he'd never heard of before his diagnosis. The disagreement is whether that allergy, not the targeted agent itself, is what actually decides which antibody partner is safe to pair it with.